Xenon Pharmaceuticals Inc.
XENE
$58.76
-$0.79-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -47.07% | -52.38% | -47.62% | -43.56% | -39.77% |
| Total Depreciation and Amortization | -8.65% | -6.15% | -0.66% | 105.38% | 12.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.47% | 16.51% | 34.08% | 12.42% | 49.86% |
| Change in Net Operating Assets | 268.49% | 2,576.32% | -23.68% | -164.10% | -2,720.75% |
| Cash from Operations | -46.79% | -55.63% | -53.88% | -55.18% | -42.98% |
| Capital Expenditure | 35.98% | 69.66% | 74.02% | 46.67% | 47.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -392.75% | -190.75% | 30.18% | 249.23% | 285.88% |
| Cash from Investing | -395.36% | -192.21% | 32.12% | 246.46% | 279.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7,085.19% | 7,120.65% | 865.48% | -95.15% | -96.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7,085.19% | 7,120.65% | 865.48% | -95.15% | -96.22% |
| Foreign Exchange rate Adjustments | 104.11% | 128.63% | 127.39% | -121.19% | 12.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,071.77% | 643.08% | 1,051.80% | 241.33% | -101.87% |